You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • FRI0162 Investigation into the binding affinity of certolizumab pegol to fcrn and functional consequences for fcrn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept

Citation Tools

Article menu
Download PDFPDF
Poster Presentation
Rheumatoid arthritis - anti-TNF therapy
FRI0162 Investigation into the binding affinity of certolizumab pegol to fcrn and functional consequences for fcrn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Baker T, Kevorkian L, Nesbitt A
FRI0162 Investigation into the binding affinity of certolizumab pegol to fcrn and functional consequences for fcrn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept
Annals of the Rheumatic Diseases 2013;72:A426.